Part of the OvaSuiteSM portfolio of blood tests, Ova1Plus® is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Ova1® is performed first, leveraging its high sensitivity1. Overa®, with its high specificity2, is automatically performed when an intermediate risk is detected.

Low Risk is <4.4 (Postmenopausal) and <5.0 (Premenopausal) Intermediate Risk is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) Markedly Elevated Risk is >6.0 (Postmenopausal) and >7.0 (Premenopausal)

Example Ova1Plus Report

Learn more about Ova1’s high performance compared to CA 125 alone!

With 4 additional biomarkers and a proprietary algorithm, Ova1 has dramatically improved performance compared to CA 125 alone.

Ova1 demonstrates improved performance across certain ethnicities, compared to CA 125 alone.4

Biomarkers in Ova1 & Overa

Arrows indicate the typical trends of biomarkers in the case of an Elevated Risk result.

Not planning for surgery?


Learn More About OvaWatch

Utilize the OvaSuite portfolio of products and confidently move from assessment to action.

A single blood draw – which can be performed at a number of national and regional laboratories or in a healthcare provider's offices using our proprietary testing kit – is all that is needed. 

Contact us to learn more, order kits, or to locate one of our phlebotomy partners.